Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31332895 | 0.80 | OPRK1 (0.33) | NPSR1OPRK1ALDH1A1KDM4EHPGD | |
| SCHEMBL31332852 | 0.75 | ALDH1A1 (0.32) | NPSR1ALDH1A1KDM4EHPGDALOX15 | |
| SCHEMBL19737998 | 0.72 | NPSR1 (0.43) | NPSR1ALDH1A1KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL24596265 | 0.68 | NPSR1 (0.39) | NPSR1ALDH1A1KDM4EMAPTNPC1 | |
| SCHEMBL29789969 | 0.68 | NPSR1 (0.39) | NPSR1ALDH1A1KDM4EMAPTMAPK1 | |
| SCHEMBL31728480 | 0.68 | TMEM97 (0.50) | NPSR1ALDH1A1LRRK2SMN1; SMN2 | |
| SCHEMBL31133209 | 0.68 | MAPK1 (0.39) | NPSR1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL24596346 | 0.67 | NPSR1 (0.38) | NPSR1ALDH1A1KDM4EHSD17B10MAPT | |
| SCHEMBL25372982 | 0.66 | ALDH1A1 (0.38) | OPRK1ALDH1A1KDM4EHPGDHSD17B10 | |
| SCHEMBL30455948 | 0.65 | MAP3K5 (0.37) | TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709374-A2 | KCC2 POTENTIATORS AND USES THEREOF | Axonis Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2024233885-A2 | KCC2 POTENTIATORS AND USES THEREOF | AXONIS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062402-A1 | KCC2 POTENTIATORS AND USES THEREOF | HCN2, HCN1, HCN4 | NPSR1 917/4885OPRK1 130/4885ALDH1A1 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.